ORCID as entered in ROS

Select Publications
2024, 'Identifying optimized assessment of nerve damage during chemotherapy.', Journal of Clinical Oncology, 42, pp. 12016 - 12016, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12016
,2024, 'Decision Regret Following the Choice of Surgery or Active Surveillance for Small, Low-Risk Papillary Thyroid Cancer: A Prospective Cohort Study', Thyroid, 34, pp. 626 - 634, http://dx.doi.org/10.1089/thy.2023.0634
,2024, 'Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes', Supportive Care in Cancer, 32, http://dx.doi.org/10.1007/s00520-024-08484-5
,2024, 'Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00690
,2024, 'Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity', Jnccn Journal of the National Comprehensive Cancer Network, 22, pp. 108 - 116, http://dx.doi.org/10.6004/jnccn.2023.7083
,2024, 'Upper-limb dysfunction in cancer survivors with chemotherapy-induced peripheral neurotoxicity', Journal of the Neurological Sciences, 457, http://dx.doi.org/10.1016/j.jns.2023.122862
,2024, 'Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial', Nature Medicine, 30, pp. 498 - 506, http://dx.doi.org/10.1038/s41591-023-02734-5
,2024, 'A Comparison of Transoral Versus Transcervical Surgical Approaches to Retropharyngeal Lymphadenectomy: A Scoping Review', Journal of Otolaryngology Head and Neck Surgery, 53, http://dx.doi.org/10.1177/19160216241265092
,2024, 'Clinical Predictors of Cisplatin Chemoradiation-Induced Ototoxicity in HPV-Positive Oropharyngeal Squamous Cell Carcinoma: A Case-Control Study', Journal of Otolaryngology Head and Neck Surgery, 53, http://dx.doi.org/10.1177/19160216241248671
,2024, 'Sleep dysfunction associated with worse chemotherapy-induced peripheral neurotoxicity functional outcomes', Supportive Care in Cancer, 32, http://dx.doi.org/10.1007/s00520-023-08245-w
,2024, '39O Four years and 1400+ patient referrals: Achievements of the Australian Rare Cancer Portal', ESMO Open, 9, pp. 102428 - 102428, http://dx.doi.org/10.1016/j.esmoop.2024.102428
,2024, 'Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck', CELL DEATH AND DIFFERENTIATION, 31, pp. 460 - 468, http://dx.doi.org/10.1038/s41418-024-01272-y
,2024, 'The Quantification of Radiation Fibrosis Using Clinically Indicated Magnetic Resonance Imaging for Head and Neck Cancer Patients', DYSPHAGIA, 39, pp. 1025 - 1034, http://dx.doi.org/10.1007/s00455-024-10678-2
,2023, 'INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)', BMC Cancer, 23, http://dx.doi.org/10.1186/s12885-023-10642-7
,2023, 'Erlotinib Plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group', Journal of Clinical Oncology, 41, pp. 4714 - 4720, http://dx.doi.org/10.1200/JCO.22.02770
,2023, 'The protective role of postoperative radiation therapy in low and intermediate grade major salivary gland malignancies: A study of the Canadian Head and Neck Collaborative Research Initiative', Cancer, 129, pp. 3263 - 3274, http://dx.doi.org/10.1002/cncr.34932
,2023, 'Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study', European Journal of Cancer, 192, http://dx.doi.org/10.1016/j.ejca.2023.113245
,2023, 'A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review', Cancers, 15, http://dx.doi.org/10.3390/cancers15174378
,2023, 'Quantifying Neck Fibrosis: Establishing the Domain Structure of the Neck Fibrosis Scale', Laryngoscope, 133, pp. 2198 - 2202, http://dx.doi.org/10.1002/lary.30497
,2023, 'HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis', Cancer Letters, 568, http://dx.doi.org/10.1016/j.canlet.2023.216286
,2023, 'Glossectomy for the treatment of oral cavity carcinoma: Quantitative, functional and patient-reported quality of life outcomes differ by four glossectomy defects', Oral Oncology, 142, http://dx.doi.org/10.1016/j.oraloncology.2023.106431
,2023, 'The effect of exercise intensity on the inflammatory profile of cancer survivors: A randomised crossover study', European Journal of Clinical Investigation, 53, pp. e13984, http://dx.doi.org/10.1111/eci.13984
,2023, 'Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer', Journal of Cancer Research and Clinical Oncology, 149, pp. 4959 - 4965, http://dx.doi.org/10.1007/s00432-022-04404-4
,2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 41, pp. 4093 - 4093, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4093
,2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.', Journal of Clinical Oncology, 41, pp. 3031 - 3031, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3031
,2023, 'Targeting translation: A review of preclinical animal models in the development of treatments for chemotherapy-induced peripheral neuropathy', Journal of the Peripheral Nervous System, 28, pp. 179 - 190, http://dx.doi.org/10.1111/jns.12544
,2023, 'The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.', Journal of Clinical Oncology, 41, pp. 3616 - 3616, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3616
,2023, 'Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial', Journal of Clinical Oncology, 41, pp. 2007 - 2019, http://dx.doi.org/10.1200/JCO.22.01134
,2023, 'Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial', Eclinicalmedicine, 58, http://dx.doi.org/10.1016/j.eclinm.2023.101897
,2023, 'Progress in the Treatment of Small Intestine Cancer', Current Treatment Options in Oncology, 24, pp. 241 - 261, http://dx.doi.org/10.1007/s11864-023-01058-3
,2023, 'Irradiation-Induced Dysbiosis: The Compounding Effect ofHigh-Fat Diet on Metabolic and Immune Functions in Mice', International Journal of Molecular Sciences, 24, pp. 5631 - 5631, http://dx.doi.org/10.3390/ijms24065631
,2023, 'Practice patterns for positive sentinel lymph node in head and neck melanoma', Head and Neck, 45, pp. 555 - 560, http://dx.doi.org/10.1002/hed.27262
,2023, 'INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)-A study led by the Australasian Gastro-intestinal Trials Group (AGITG).', JOURNAL OF CLINICAL ONCOLOGY, 41, pp. LBA294 - LBA294
,2023, 'Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review', Journal of Cancer Survivorship, 17, pp. 222 - 236, http://dx.doi.org/10.1007/s11764-021-00988-x
,2023, 'Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes', Jnccn Journal of the National Comprehensive Cancer Network, 21, pp. 125 - 132, http://dx.doi.org/10.6004/jnccn.2022.7074
,2023, 'Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy', Asia-Pacific Journal of Clinical Oncology, 19, pp. 243 - 249, http://dx.doi.org/10.1111/ajco.13834
,2023, 'Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors', Journal for Immunotherapy of Cancer, 11, http://dx.doi.org/10.1136/jitc-2022-006136
,2023, 'ASCO's Leadership Development Program: Focusing on the Next Generation of Leaders in Asia Pacific', JCO Global Oncology, 9, http://dx.doi.org/10.1200/GO.22.00313
,2023, 'Associations between Human Papillomavirus Status, Weight Change, and Survival of Oropharyngeal Cancer Patients', Nutrition and Cancer, 75, pp. 1541 - 1550, http://dx.doi.org/10.1080/01635581.2023.2212427
,2023, 'Investigation into the genetics of fetal congenital lymphatic anomalies', PRENATAL DIAGNOSIS, 43, pp. 703 - 716, http://dx.doi.org/10.1002/pd.6345
,2023, 'The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers', ANNALS OF ONCOLOGY, 34, pp. S450 - S450, http://dx.doi.org/10.1016/j.annonc.2023.09.1824
,2022, 'Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU)', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.1060957
,2022, 'Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients', Clinical Autonomic Research, 32, pp. 497 - 506, http://dx.doi.org/10.1007/s10286-022-00895-w
,2022, 'Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers', Asia Pacific Journal of Clinical Oncology, 18, pp. 660 - 668, http://dx.doi.org/10.1111/ajco.13745
,2022, 'Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study', Journal of Translational Medicine, 20, http://dx.doi.org/10.1186/s12967-022-03754-4
,2022, 'Reproducibility and Reliability of Subbasal Corneal Nerve Parameters of the Inferior Whorl in the Neurotoxic and Healthy Cornea', Cornea, 41, pp. 1487 - 1494, http://dx.doi.org/10.1097/ICO.0000000000002947
,2022, 'Abstract B076: βIII-Tubulin is a brake on extrinsic cell-death in pancreatic cancer', Cancer Research, 82, pp. B076 - B076, http://dx.doi.org/10.1158/1538-7445.panca22-b076
,2022, 'Abstract C073: CRO-67 is a novel therapeutic for pancreatic cancer: Implications for tumor and stromal reprogramming', Cancer Research, 82, pp. C073 - C073, http://dx.doi.org/10.1158/1538-7445.panca22-c073
,2022, 'Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use', Quality of Life Research, 31, pp. 3091 - 3107, http://dx.doi.org/10.1007/s11136-022-03154-7
,2022, 'Tear film substance P in patients treated with neurotoxic chemotherapy', Experimental Eye Research, 224, http://dx.doi.org/10.1016/j.exer.2022.109253
,